ORLANDO (EGMN) - The data are out, and there is no getting around the failure of bevacizumab to make a significant improvement in disease-free survival at 3 years for early-stage colon cancer patients in a large, much-anticipated clinical trial. After a median follow-up of 36 months, 77.4% of patients were disease-free if they had the targeted therapy added to a modified FOLFOX6 chemotherapy regimen - little better than the 75.5% disease-free survival rate in patients given FOLFOX6 alone.All hope...